DMPX: Difference between revisions
Appearance
Content deleted Content added
No edit summary |
Digressivo (talk | contribs) m added wiki-link |
||
(18 intermediate revisions by 14 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{Drugbox |
{{Drugbox |
||
| drug_name = |
| drug_name = |
||
| IUPAC_name = 3,7-Dimethyl-1-(2-propyn-1-yl)-3,7-dihydro-1''H''-purine-2,6-dione |
|||
| IUPAC_name = |
|||
| image = |
| image = DMPX.svg |
||
| width = |
| width = 175 |
||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = |
| tradename = |
||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
||
| pregnancy_US = <!-- A / B / C / D / X --> |
| pregnancy_US = <!-- A / B / C / D / X --> |
||
Line 16: | Line 17: | ||
| CAS_number_Ref = {{cascite|correct|??}} |
| CAS_number_Ref = {{cascite|correct|??}} |
||
| CAS_number = 14114-46-6 |
| CAS_number = 14114-46-6 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
⚫ | |||
| UNII = 5YFR5SPS6T |
|||
⚫ | |||
| PubChem = 99562 |
| PubChem = 99562 |
||
| ChemSpiderID = 89948 |
|||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=10 | H= |
| C=10 | H=10 | N=4 | O=2 |
||
⚫ | |||
| molecular_weight = 220.227 g/mol |
|||
| StdInChI = 1S/C10H10N4O2/c1-4-5-14-9(15)7-8(11-6-12(7)2)13(3)10(14)16/h1,6H,5H2,2-3H3 |
|||
⚫ | |||
| StdInChIKey = IORPOFJLSIHJOG-UHFFFAOYSA-N |
|||
}} |
}} |
||
⚫ | '''DMPX''' ('''3,7-dimethyl-1-propargylxanthine''') is a [[caffeine]] [[Structural analog|analog]] which displays affinity to A<sub>2</sub> [[adenosine receptor]]s, in contrast to the A<sub>1</sub> subtype receptors.<ref name=DMPX>{{cite journal | vauthors = Seale TW, Abla KA, Shamim MT, Carney JM, Daly JW | title = 3,7-Dimethyl-1-propargylxanthine: a potent and selective in vivo antagonist of adenosine analogs | journal = Life Sciences | volume = 43 | issue = 21 | pages = 1671–84 | date = 1988 | pmid = 3193854 | doi = 10.1016/0024-3205(88)90478-x }}</ref> DMPX had 28× and 15× higher potency than caffeine in blocking peripheral and central [[5′-(N-ethylcarboxamido)adenosine|NECA]]-responses. The locomotor stimulation caused by DMPX (ED<sub>50</sub> 10 ''μ''mol/kg) was similarly higher than caffeine.<ref name=DMPX /> |
||
==See also== |
|||
⚫ | '''DMPX''' ('''3,7- |
||
* [[Dipropylcyclopentylxanthine|DPCPX]] |
|||
* [[8-Phenyltheophylline|8-PT]] |
|||
* [[8-Cyclopentyl-1,3-dimethylxanthine|CPX]] (8-CPT) |
|||
* [[8-Chlorotheophylline]] |
|||
* [[Theophylline]] |
|||
==References== |
==References== |
||
Line 32: | Line 43: | ||
{{Stimulants}} |
{{Stimulants}} |
||
{{Nootropics}} |
|||
{{Adenosinergics}} |
{{Adenosinergics}} |
||
⚫ | |||
[[Category:Adenosine receptor antagonists]] |
[[Category:Adenosine receptor antagonists]] |
||
[[Category:Anxiogenics]] |
[[Category:Anxiogenics]] |
||
[[Category: |
[[Category:Caffeine]] |
||
⚫ | |||
[[Category:Designer drugs]] |
[[Category:Designer drugs]] |
||
⚫ | |||
⚫ |
Latest revision as of 18:11, 15 May 2024
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.162.258 |
Chemical and physical data | |
Formula | C10H10N4O2 |
Molar mass | 218.216 g·mol−1 |
3D model (JSmol) | |
| |
|
DMPX (3,7-dimethyl-1-propargylxanthine) is a caffeine analog which displays affinity to A2 adenosine receptors, in contrast to the A1 subtype receptors.[1] DMPX had 28× and 15× higher potency than caffeine in blocking peripheral and central NECA-responses. The locomotor stimulation caused by DMPX (ED50 10 μmol/kg) was similarly higher than caffeine.[1]
See also
[edit]- DPCPX
- 8-PT
- CPX (8-CPT)
- 8-Chlorotheophylline
- Theophylline